Although the involvement of early and late ROS in cancer cells survival to chemotherapeutic agents is a novel finding, VEGF-A has already been involved in an autocrine survival loop in hypoxic colon cancer cells [40]. Here, VEGFA is linked to malignant colon neoplasm.